Mark Cochran

Mark Cochran has a vast experience in life sciences across pharmaceutical and biotechnology industries, encompassing research, drug development, business development, and venture capital.

Specializing in pharmaceutical business development, product development, research and development, project management, and contract negotiation, among other areas.

Educational background includes an MSc from the University of Guelph, a PhD from Queen's University, and a BSc from the University of Toronto - University of St. Michael's College.

Mark has held significant roles like Chairman Of The Board at iFabric Corp., Managing Director at Johns Hopkins Medicine, CEO/Executive Director at Blanchette Rockefeller Neurosciences Institute, Vice President at MDS Capital Corp, and more.

His expertise covers molecular biology, neuroscience, gene expression, virology, vaccines, and biotechnology, as well as start-up company formation, financing, and venture capital.

Mark Cochran's previous affiliations include Board Member at Microbix, Director/Chief Business Officer at Microbix, Executive Director at University Health Associates, Director at Acumen Pharmaceuticals, and VP Business Development at Bayer HealthCare and Bayer Pharmaceuticals.

He has also been involved in gene therapy, biological drugs, recombinant protein, fermentation, human monoclonal antibodies, transgenic animals, SBIR, and pharma partnering.